BioPharmSignal logoBioPharmSignal

Biotech News

T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

T2 Biosystems (TTOO)T2 BiosystemsCompany update

Milestone demonstrates the growing customer adoption of the Company’s proprietary technology LEXINGTON, Mass. , Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it

Related news

INBSIntelligent Bio Solutions2026-07-23 12:30 EST

Intelligent Bio Solutions Achieves Key Milestone Ahead of Planned FDA 510(k) Submission, Advancing Toward Planned U.S. Market Entry

OSUROraSure Technologies, Inc.2026-07-21 20:30 EST

OraSure Receives Emergency Use Authorization for Second Generation Ebola Test

OSUROraSure Technologies, Inc.2026-02-10 13:05 EST

OraSure to Launch OraQuick™ HIV Self-Test in Canada

View all latest news

T2 Biosystems

T2 Biosystems is a medical diagnostics company focused on rapid pathogen detection and bloodstream infection testing. Its business is centered on delivering fast diagnostic information to clinical settings.

Recent company news

TTOOT2 Biosystems2025-01-07 14:00 EST

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

TTOOT2 Biosystems2024-12-18 14:00 EST

T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

TTOOT2 Biosystems2024-12-17 14:00 EST

T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

TTOOT2 Biosystems2024-12-16 14:00 EST

T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.

TTOOT2 Biosystems2024-12-09 14:00 EST

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

Stock data

Close
0.00 USD
Market cap
—
Exchange
NASDAQ
Sector
MedTech
Location
United States